News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>UBS Adds MAOYAN ENT (01896.HK) TP to $12.5 on Excellent Movie Content Pipeline for 2024
MAOYAN ENT (01896.HK)'s 2023 revenue rallied 105% YoY, in line with the market's expectation, UBS released a research report saying. Adjusted net profit shot up 342% YoY, w...
Reset
Send
The window will close in 5 seconds
<Research>UBS Adds MAOYAN ENT (01896.HK) TP to $12.5 on Excellent Movie Content Pipeline for 2024
Close
Recommend
2
Positive
4
Negative
2
 
SHORT SELL
 
STOCK INFO

MAOYAN ENT (01896.HK)  +0.270 (+3.814%)    Short selling $3.04M; Ratio 9.781%   's 2023 revenue rallied 105% YoY, in line with the market's expectation, UBS released a research report saying.

Adjusted net profit shot up 342% YoY, which is higher than the expectations of UBS and the market by 11-12%, which is believed to be driven by the effectiveness of cost control measures and other financial gains during the period.

UBS expected that the accumulated demand for offline performance activities will help boost the Company's market share gain. Coupled with an excellent movie content pipeline this year, a number of key blockbusters are set to be released within 2024.

It is estimated that MAOYAN ENT's overall online ticketing revenue will grow by 3% in the whole 2024. Therefore, UBS added its target price from $12.05 to $12.5, with rating kept at Buy.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-27 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.